Table 1.
Baseline characteristics of dialyzed patients with COVID-19
| Characteristics | All patients (n = 44) |
WHO score (2–4) |
WHO score = 5 |
WHO score ≥ 6 |
P |
|---|---|---|---|---|---|
| No oxygen (n = 11, 25%) |
O2 ≤ 6 l/min (n = 14, 31.8%) |
O2 ≥ 9 l/min (n = 19, 43.2%) |
|||
| Demographic data | |||||
| Men | 29 (65.9) | 4 (36.4) | 11 (78.6) | 14 (73.7) | 0.06 |
| Age, yr | 61 (51.5–72.5) | 52 (39–69) | 65.5 (58–76) | 64 (52–73) | ns |
| >65 yr | 19 (43.2) | 3 (27.3) | 7 (50) | 9 (47.4) | ns |
| BMI, kg/m2 | 26.3 (23.45–31.1) | 24.1 (19.8–31.4) | 28.45 (24–31.5) | 26.5 (23.5–30.9) | ns |
| Duration of dialysis, mo | 36.5 (12–75) | 43 (9–58) | 50 (10–75) | 36 (14–84) | ns |
| Underlying CKD | |||||
| Diabetic nephropathy | 9 (20.5) | 2 (18.2) | 2 (14.3) | 5 (26.3) | ns |
| Vascular nephropathy | 9 (20.5) | 2 (18.2) | 4 (28.6) | 3 (15.8) | ns |
| Mixt nephropathya | 7 (15.9) | 1 (9.1) | 2 (14.3) | 4 (21.1) | ns |
| Glomerular disease | 6 (13.6) | 0 (0.0) | 2 (14.3) | 4 (21.1) | ns |
| Polycystic kidney disease | 4 (9.1) | 2 (18.2) | 2 (14.3) | 0 (0.0) | ns |
| Undetermined | 5 (11.4) | 3 (27.3) | 1 (7.1) | 1 (5.3) | ns |
| Other | 4 (9.1) | 1 (9.1) | 1 (7.1) | 2 (10.5) | ns |
| Coexisting comorbid conditions | |||||
| Obesity, BMI >30 kg/m2 | 15 (34.1) | 3 (27.3) | 6 (42.9) | 6 (31.6) | ns |
| Hypertension | 43 (97.7) | 11 (100.0) | 14 (100.0) | 18 (94.7) | ns |
| ACEI | 13 (29.5) | 3 (27.3) | 6 (42.9) | 4 (21.1) | ns |
| ARB | 8 (18.2) | 1 (9.1) | 3 (21.4) | 4 (21.1) | ns |
| Diabetes mellitus | 22 (50) | 5 (45.5) | 4 (28.6) | 13 (68.4) | 0.07 |
| Dyslipidemia | 26 (59.1) | 5 (45.5) | 9 (64.3) | 12 (63.2) | ns |
| Smoking | 15 (34.1) | 10 (90.9) | 9 (64.3) | 10 (52.6) | ns |
| Chronic respiratory disease | 12 (27.3) | 3 (27.3) | 4 (28.6) | 5 (26.3) | ns |
| Chronic cardiac disease | 17 (38.6) | 3 (27.3) | 7 (50.0) | 7 (36.8) | ns |
| Cancer | 8 (18.2) | 1 (9.1) | 4 (28.6) | 3 (15.8) | ns |
| ≥2 comorbidities | 38 (86.4) | 8 (72.7) | 12 (85.7) | 18 (94.7) | ns |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; ns, nonsignificant P value; WHO, World Health Organization.
Data are n (%) or median (interquartile range).
a
Mixt refers to diabetic and vascular nephropathy.